Gary Raskob

Summary

Affiliation: University of Oklahoma Health Sciences Center
Country: USA

Publications

  1. ncbi Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials
    G E Raskob
    University of Oklahoma Health Sciences Center, College of Public Health, 801 NE 13th Street, Oklahoma City, Oklahoma 73104, USA
    J Bone Joint Surg Br 94:257-64. 2012
  2. ncbi Scoring and psychometric validation of the Perception of Anticoagulant Treatment Questionnaire (PACT-Q)
    M H Prins
    The Department of Epidemiology, Care and Public Health Research Institutes, University of Maastricht, Maastricht, The Netherlands
    Health Qual Life Outcomes 7:30. 2009
  3. ncbi Surveillance for deep vein thrombosis and pulmonary embolism: recommendations from a national workshop
    Gary E Raskob
    College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73190, USA
    Am J Prev Med 38:S502-9. 2010
  4. ncbi Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery
    Gary E Raskob
    College of Public Health, Department of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, 801 NE Thirteenth Street, Room 139, Oklahoma City, OK 73104, USA
    Chest 124:379S-385S. 2003
  5. ncbi Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study
    Gary Raskob
    College of Public Health, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA
    Thromb Haemost 104:642-9. 2010
  6. ncbi Helical computed tomography and magnet resonance imaging: diagnosis of pulmonary embolism in symptomatic patients
    Steve Blevins
    University of Oklahoma Health Sciences Center, Oklahoma City 73190, OK, USA
    Curr Opin Hematol 10:345-50. 2003
  7. ncbi Initial management of immune thrombocytopenic purpura in adults: a randomized controlled trial comparing intermittent anti-D with routine care
    James N George
    Department of Medicine, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73190, USA
    Am J Hematol 74:161-9. 2003
  8. ncbi Clinical utility of D-dimer in patients with suspected pulmonary embolism and nondiagnostic lung scans or negative CT findings
    Suman W Rathbun
    Department of Medicine, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City 73104, USA
    Chest 125:851-5. 2004
  9. ncbi Negative D-dimer result to exclude recurrent deep venous thrombosis: a management trial
    Suman W Rathbun
    Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA
    Ann Intern Med 141:839-45. 2004
  10. ncbi Chemical (VX) terrorist threat: public knowledge, attitudes, and responses
    J Neil Henderson
    Department of Health Promotion Sciences College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73190, USA
    Biosecur Bioterror 2:224-8. 2004

Research Grants

  1. OU Human Research Protection Program
    Gary Raskob; Fiscal Year: 2002
  2. OU Human Research Protection Program, Year 2
    Gary Raskob; Fiscal Year: 2003
  3. OU Developmental Center for Injury Prevention Research
    Gary Raskob; Fiscal Year: 2005

Detail Information

Publications20

  1. ncbi Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials
    G E Raskob
    University of Oklahoma Health Sciences Center, College of Public Health, 801 NE 13th Street, Oklahoma City, Oklahoma 73104, USA
    J Bone Joint Surg Br 94:257-64. 2012
    ..4%) apixaban patients and 206 (4.9%) enoxaparin patients (risk difference -0.6% (95% CI -1.5 to 0.3)). Apixaban 2.5 mg twice daily is more effective than enoxaparin 40 mg once daily without increased bleeding...
  2. ncbi Scoring and psychometric validation of the Perception of Anticoagulant Treatment Questionnaire (PACT-Q)
    M H Prins
    The Department of Epidemiology, Care and Public Health Research Institutes, University of Maastricht, Maastricht, The Netherlands
    Health Qual Life Outcomes 7:30. 2009
    ..This questionnaire needs to be finalised and psychometrically validated...
  3. ncbi Surveillance for deep vein thrombosis and pulmonary embolism: recommendations from a national workshop
    Gary E Raskob
    College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73190, USA
    Am J Prev Med 38:S502-9. 2010
    ....
  4. ncbi Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery
    Gary E Raskob
    College of Public Health, Department of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, 801 NE Thirteenth Street, Room 139, Oklahoma City, OK 73104, USA
    Chest 124:379S-385S. 2003
    ....
  5. ncbi Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study
    Gary Raskob
    College of Public Health, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA
    Thromb Haemost 104:642-9. 2010
    ..The incidence of clinically relevant bleeding was low and similar across the groups. Oral edoxaban once daily is effective for preventing VTE after total hip replacement...
  6. ncbi Helical computed tomography and magnet resonance imaging: diagnosis of pulmonary embolism in symptomatic patients
    Steve Blevins
    University of Oklahoma Health Sciences Center, Oklahoma City 73190, OK, USA
    Curr Opin Hematol 10:345-50. 2003
    ..Further studies are needed to delineate the role of magnetic resonance imaging in the management of patients with suspected pulmonary embolism...
  7. ncbi Initial management of immune thrombocytopenic purpura in adults: a randomized controlled trial comparing intermittent anti-D with routine care
    James N George
    Department of Medicine, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73190, USA
    Am J Hematol 74:161-9. 2003
    ..However, compliance with this anti-D regimen was not feasible for many patients and/or their physicians...
  8. ncbi Clinical utility of D-dimer in patients with suspected pulmonary embolism and nondiagnostic lung scans or negative CT findings
    Suman W Rathbun
    Department of Medicine, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City 73104, USA
    Chest 125:851-5. 2004
    ..We conducted a prospective cohort study that evaluated the clinical utility (usefulness) of an automated quantitative d-dimer test in the diagnosis of patients with suspected pulmonary embolism...
  9. ncbi Negative D-dimer result to exclude recurrent deep venous thrombosis: a management trial
    Suman W Rathbun
    Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA
    Ann Intern Med 141:839-45. 2004
    ..Measurement of plasma d-dimer by using an automated quantitative assay may be useful as a rapid exclusion test in patients with suspected recurrent DVT...
  10. ncbi Chemical (VX) terrorist threat: public knowledge, attitudes, and responses
    J Neil Henderson
    Department of Health Promotion Sciences College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73190, USA
    Biosecur Bioterror 2:224-8. 2004
    ..In addition, local television meteorologists were identified as a category of trusted conveyers of important information in relation to chemical terrorist attacks...
  11. ncbi Exclusion of first-episode deep-vein thrombosis after-hours using D-dimer
    Suman W Rathbun
    Cardiovascular Section, Department of Medicine, College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA
    Blood Coagul Fibrinolysis 18:795-800. 2007
    ....
  12. ncbi Prevention of central venous catheter-associated thrombosis: a meta-analysis
    Angelia Kirkpatrick
    Department of Medicine, Cardiovascular Section, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
    Am J Med 120:901.e1-13. 2007
    ..Anticoagulant prophylaxis in patients with central venous catheters is controversial. We performed a meta-analysis of randomized controlled trials of anticoagulant prophylaxis in patients with central venous catheters...
  13. ncbi Sensitivity and specificity of ultrasonography in the diagnosis of upper extremity deep vein thrombosis: a systematic review
    Bisher O Mustafa
    Department of Medicine, Room WP 3120, The University of Oklahoma Health Sciences Center, 920 Stanton L. Young Blvd, Oklahoma City, OK 73104, USA
    Arch Intern Med 162:401-4. 2002
    ..CONCLUSION: The safety of withholding anticoagulant treatment in a patient with suspected upper extremity deep vein thrombosis and negative ultrasonographic results is uncertain...
  14. ncbi ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients
    Sara K Vesely
    Hematology-Oncology Section, The University of Oklahoma Health Sciences Center, PO Box 26901, Oklahoma City, OK 73190, USA
    Blood 102:60-8. 2003
    ..Therefore, severe ADAMTS13 deficiency does not detect all patients who may be appropriately diagnosed with TTP-HUS and who may respond to plasma exchange treatment...
  15. ncbi Extended prophylaxis of venous thromboembolism with idraparinux
    Harry R Buller
    Academic Medical Center, Department of Vascular Medicine, F4 211, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    N Engl J Med 357:1105-12. 2007
    ..We evaluated the efficacy and safety of a 6-month extension of prophylaxis against recurrent venous thromboembolism with idraparinux in patients who had initially received 6 months of prophylaxis with an anticoagulant...
  16. ncbi Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    Clive Kearon
    Hamilton Health Sciences, Henderson Division, 711 Concession Street, Hamilton, Ontario, Canada
    Chest 133:454S-545S. 2008
    ..For extensive superficial vein thrombosis, we recommend treatment with prophylactic or intermediate doses of LMWH or intermediate doses of UFH for 4 weeks (Grade 1B)...
  17. ncbi Challenges in the diagnosis of acute pulmonary embolism
    Paul D Stein
    Department of Research, St Joseph Mercy Oakland Hospital, Pontiac, Mich, USA
    Am J Med 121:565-71. 2008
    ..A patient-specific approach to the diagnosis of pulmonary embolism can be taken safely in hemodynamically stable patients to increase efficiency and decrease cost and exposure to radiation...
  18. ncbi Duration of warfarin in pulmonary embolism
    Andrew Miller
    Chest 130:299; author reply 299-300. 2006
  19. ncbi Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
    Harry R Buller
    Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands
    Chest 126:401S-428S. 2004
    ..For most patients with pulmonary embolism (PE), we recommend clinicians not use systemic thrombolytic therapy (Grade 1A). For the duration and intensity of treatment for PE, the recommendations are similar to those for DVT...
  20. ncbi Idraparinux versus standard therapy for venous thromboembolic disease
    Harry R Buller
    Academic Medical Center, Department of Vascular Medicine, F4 211, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    N Engl J Med 357:1094-104. 2007
    ..We investigated the potential use of idraparinux, a long-acting inhibitor of activated factor X, as a substitute for standard therapy...

Research Grants3

  1. OU Human Research Protection Program
    Gary Raskob; Fiscal Year: 2002
    ..The University of Oklahoma is committed to maintaining these initiatives after the term of this award. ..
  2. OU Human Research Protection Program, Year 2
    Gary Raskob; Fiscal Year: 2003
    ..The University of Oklahoma is committed to maintaining these initiatives after the term of this award. ..
  3. OU Developmental Center for Injury Prevention Research
    Gary Raskob; Fiscal Year: 2005
    ..abstract_text> ..